Delivery Order SPE2DP20D0002-SPE2DP25F109X
Award Date 9/8/25
Potential Completion Date 9/23/25
Potential Value $165K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Teva Pharmaceuticals USA, Inc. has been awarded a $1,526,969 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to supply adenovirus type 4 vaccine. This delivery order was issued under an existing contract vehicle and will support the immunization programs of the military. Teva will deliver the vaccine products to the agency's location in Parsippany, New Jersey by December 19, 2023. As a major pharmaceutical manufacturer, Teva has extensive experience...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $660,627.72 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on August 12, 2025, with an ultimate completion date of August 26, 2025. This firm-fixed-price delivery order, issued without set-aside designation, represents continued federal procurement from Teva as a critical supplier of vaccines and pharmaceutical products to military immunization programs. The contract will be performed at...
- Teva Pharmaceuticals USA, Inc., headquartered in Parsippany, New Jersey, was awarded a delivery order valued at $825,784.65 for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. This firm-fixed-price contract, issued without a set-aside designation, supports the Medical Supply Chain within the Department of Defense. The delivery order represents a continuation of Teva's established role as a critical supplier of the Adenovirus Type 4...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $825,784.65 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, and performance will be executed at Teva's facility in Parsippany, New Jersey. This delivery order is issued under a larger indefinite delivery vehicle and...
- Teva Pharmaceuticals USA, Inc. has been awarded a $305,393.76 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to provide adenovirus type 4 vaccine. Performance will take place in Parsippany, New Jersey through December 2023. This delivery order was issued against an existing contract vehicle and supports the immunization programs of the military. Teva Pharmaceuticals has a history of partnering with subcontractors and receiving contract awards to supply...
- The Defense Logistics Agency (DLA) Troop Support Medical has awarded Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, a $476,414.19 firm-fixed-price delivery order to provide Adenovirus Type 4 vaccine. The contract has a completion date of February 27, 2024. Teva Pharmaceuticals USA, Inc. is a subsidiary of the global pharmaceutical company Teva Pharmaceutical Industries Ltd. and has been awarded numerous prime contracts by federal agencies such as the...
- The U.S. Defense Logistics Agency Troop Support Medical awarded Teva Pharmaceuticals USA, Inc. a $141,176.88 firm-fixed price delivery order for adenovirus type 4 vaccine. This order is not associated with a set-aside program. Teva Pharmaceuticals USA, Inc. is a pharmaceutical manufacturer that has provided various drug products, including vaccines, antiviral medications, respiratory treatments, and multiple sclerosis drugs to federal customers like the Department of Defense and Department of...
- The U.S. Department of Defense's Medical Supply Chain awarded a $660,627.72 firm-fixed-price delivery order to Teva Pharmaceuticals USA, Inc. on September 8, 2025, for the supply of Adenovirus Type 4 vaccine. The contract, issued without set-aside designation, is scheduled for completion by September 23, 2025, with performance conducted at Teva's facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as a critical supplier of the Adenovirus...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $635,218.92 firm fixed-price delivery order (SPE2DP24F7177) to Teva Pharmaceuticals USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of Adenovirus Type 4 vaccine. This order is part of a larger Indefinite Delivery Contract (SPE2DP20D0002) held by Teva to provide essential medications to federal agencies such as the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, and...
- Teva Pharmaceuticals USA, Inc. was awarded a Firm Fixed Price Delivery Order by the Defense Logistics Agency Troop Support Medical to provide Adenovirus Type 4 vaccine in Parsippany, New Jersey. The contract has a potential value of $146,823.93 and a completion date of December 20, 2022. Teva is a foreign-owned, for-profit manufacturer that has a history of providing pharmaceutical products, including vaccines and respiratory treatments, to various federal customers such as the Department of...